The Board's Role in Cyber Security


A cyber-attack can swiftly put an organisation on its knees, causing huge amounts of damage both reputationally and financially. 

In this article, Criticaleye speaks to Bill Payne, a Board Mentor at Criticaleye and former Non-executive Chair of Atento and Reece Donovan, CEO of Iomart Group, about what Boards need to get right and some of the key questions to ask, such as: 

• When was the last penetration test?
• What did it reveal?
• What are the vulnerabilities in all our systems?
• What insurance cover do we have in place?

Share this with your Community



Contributors
Bill Payne
Board Mentor
Criticaleye
Reece Donovan
CEO / Director
Mayden


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | Stepping Up to CFO – Five Key Tips

How do finance leaders prepare for a Group CFO role? At a recent Criticaleye Aspiring Group CFO Masterclass, a number of consistent themes emerged around what differen...


Inspiring Leaders Podcast: Building Beyond Borders – Leadership and Expansion Strategy (ft. Nick Burns)

Nick Burns, CEO of Reward Gateway | Edenred, joins Criticaleye’s Senior Editor Bridgette Hall to share his perspective on what it takes to deliver successful international expansion in today’s complex bus...


Click here to download this insight

Cybersecurity Risk Oversight: A Governance Guide for Board Directors

Cyber risk has shifted from a technical issue to a core business threat. This report by CrowdStrike offers practical guidance to help Boards strengthen oversight and define what 'good' looks like. Key takeawa...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 216




British Land Lightsource bp Drax Group plc LACE Partners E.ON UK NatWest Group AlixPartners Worldpay CrowdStrike Aldermore Group Mayborn Group Legal & General NATS London Stock Exchange Group Hitachi Solutions Stream Canaccord Genuity Group Inc Rolls-Royce GlaxoSmithKline plc